Dorota Zarębska-Michaluk
机构: Clinic of Infectious Diseases Kielce
每年引用次数
引用次数
引用: 2,103
H-指数: 25
I10-指数 : 67
出版物: 229
The impact of obesity and liver steatosis on the rate of liver fibrosis among patients with chronic hepatitis C
W. Kryczka , D. Zarębska-Michaluk , A. Urbaniak , M. Chrapek
Medical Science Monitor 9 ( 2) 9
6
2003
Follow-up of patients with chronic hepatitis C who discontinued antiviral treatment because of side effects
W. Kryczka , D. Zarębska-Michaluk , K. Paluch
Medical Science Monitor 9 ( 2) 10
2003
Impact of antiviral therapy on the liver steatosis in patients with chronic hepatitis c (chc).
W. Kryczka , D. Zarębska-Michaluk , A. Urbaniak , K. Paluch
Medical Science Monitor 9 ( 2) 10
2003
Real life results of direct acting antiviral therapy for HCV infection in HIV-HCV-coinfected patients: Epi-Ter2 study.
A. Piekarska , E. Jabłonowska , A. Garlicki , M. Sitko
Aids Care-psychological and Socio-medical Aspects of Aids\/hiv 32 ( 6) 762 -769
4
2020
Treatment of HCV infection in Poland at the beginning of the interferon-free era-the EpiTer-2 study.
R. Flisiak , D. Zarębska-Michaluk , E. Janczewska , A. Staniaszek
Journal of Viral Hepatitis 25 ( 6) 661 -669
15
2018
Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study.
R. Flisiak , E. Janczewska , M. Łucejko , E. Karpińska
Journal of Viral Hepatitis 25 ( 11) 1298 -1305
10
2018
Real‐world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study
R. Flisiak , E. Janczewska , M. Wawrzynowicz-Syczewska , J. Jaroszewicz
Alimentary Pharmacology & Therapeutics 44 ( 9) 946 -956
61
2016
Extrahepatic manifestations associated with chronic hepatitis C infections in Poland.
DA Zarebska-Michaluk , DM Lebensztejn , WM Kryczka , E Skiba
Advances in Medical Sciences 55 ( 1) 67 -73
12
2010
VIII Congress of the Polish Association for the Study of the Liver: 6-8 June 2019 Mikołajki
M Bura , A Bura , I Mozer-Lisewska , J Cielecka-Kuszyk
Clinical and Experimental Hepatology 5 ( 2) 171 -194
2019
Effi cacy of combined antiviral therapy with interferon α and ribavirin in chronic hepatitis C patients with extrahepatic manifestations
D Zarębska-Michaluk , DM Lebensztejn , W Kryczka
Medical Science Monitor 3 ( 2) AB21 -AB21
2007
Extrahepatic manifestations associated with chronic hepatitis C infection in south-eastern Poland
D Zarębska-Michaluk , DM Lebensztejn , W Kryczka
Medical Science Monitor 3 ( 2) AB21 -AB21
2007
Characteristics of patients and effectiveness of chronic hepatitis C treatment during the initial 4 years of access to interferon-free therapy
Robert Flisiak , Beata Lorenc , J Klapaczyński , Ewa Janczewska
J Hepatology 70 ( Suppl 1) E222 -E223
2
2019
Beethoven's tale shall encourage novel research on chronic HBV infection, not lead intoxication.
P Rzymski , D Zarębska-Michaluk , R Flisiak
The Journal of Infection S0163 -4453 (23) 00597
2023
i in.(2016) Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in hepatitis C: AMBER study
R Flisiak , E Janczewska , M Wawrzynowicz-Syczewska , J Jaroszewicz
Aliment. Pharmacol. Ther
Thyroid gland dysfunctions during antiviral therapy of chronic hepatitis C.
W Kryczka , A Kowalska , D Zarebska-Michaluk , E Brojer
Medical Science Monitor 221 -225
17
2001
Effectiveness of antiviral treatment of patients with chronic hepatitis C (a Polish multicenter study)
W Kryczka , B Adamek , B Bolewska , J Juszczyk
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 11 ( 64) 340 -343
2001
HEPATITIS C VIRUS–Natural history and epidemiology
L Ouaguia , O Morales , C Wychowski , A Carpentier
Does hospitalization change the perception of COVID-19 vaccines among unvaccinated patients? Vaccines 2022; 10: 476
D Zarebska-Michaluk , P Rzymski , A Moniuszko-Malinowska , M Brzdek
s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affil-iations.
1
2022
Global Elimination of HCV—Why Is Poland Still So Far from the Goal? Viruses 2023, 15, 2067
O Tronina , M Panczyk , D Zarebska-Michaluk , J Gotlib
2023
Treatment of HBV/HCV coinfection
W Kryczka , D Zarebska-Michaluk , A Wieczorek , P Pabjan
Medical Science Monitor 3 ( 2) AB21 -AB22
2007